Choose language

mimovax and fp6 logo

Welcome to the MimoVax project

European Team led by AFFiRiS AG is developing Alzheimer’s Vaccine

The MimoVax Consortium met in Vienna to present final project results

The EU-project MimoVax aims to cure patients through vaccination. This could be the first safe and efficacious treatment to halt progression of this crippling disease.

The cornerstone of the new vaccination strategy is the proprietary AFFITOM® technology of AFFiRiS AG, a biotech company based in Vienna. Compared to conventional approaches AFFITOM® allows fast, cost-effective and safe vaccine development.

The project started in October 2006 and ended in December 2011 with 2.4 M€ from the EC and a 2.0 M€ contribution by the participating SME. This 51 months STREP was coordinated by AFFiRiS AG and will concluded with a phase I clinical trial for the AD vaccine.


Find out more

Supported by the EC’s FP6 through Contract No. LSHB-CT-2006-037702


MimoVax illustrates:

The Project

What causes Alzheimer's disease and how could MimoVax help?

See more ...